246 related articles for article (PubMed ID: 10949634)
1. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Comans EF; Hoekstra OS; Hoekman K; van der Hoeven JJ; Golding RP; Teule GJ
Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1520-8. PubMed ID: 10949634
[TBL] [Abstract][Full Text] [Related]
2. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Soepenberg O
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1979-80. PubMed ID: 11048563
[No Abstract] [Full Text] [Related]
3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
5. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of FDG-PET in oncology.
Czernin J
Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
10. FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions.
Halter G; Storck M; Guhlmann A; Frank J; Grosse S; Liewald F
Thorac Cardiovasc Surg; 2000 Apr; 48(2):97-101. PubMed ID: 11028711
[TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography fusion imaging in brown adipose tissue.
Minotti AJ; Shah L; Keller K
Clin Nucl Med; 2004 Jan; 29(1):5-11. PubMed ID: 14688591
[TBL] [Abstract][Full Text] [Related]
14. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
16. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging.
Yen RF; Hung RL; Pan MH; Wang YH; Huang KM; Lui LT; Kao CH
Cancer; 2003 Jul; 98(2):283-7. PubMed ID: 12872346
[TBL] [Abstract][Full Text] [Related]
17. [The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].
Granov AM; Tiushin LA; Tlostanova MS; Kostenikov NA; Ryzhkova DV; Savello VE; Stanzhevskiĭ AA
Vopr Onkol; 2003; 49(5):563-73. PubMed ID: 14682126
[TBL] [Abstract][Full Text] [Related]
18. [Present status of PET images: clinical FDG PET in oncology].
Inoue T
Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
[TBL] [Abstract][Full Text] [Related]
19. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
20. [18F FDG PET- applications in oncology].
Răileanu I; Rusu V; Stefănescu C; Cinotti L
Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
